Pharmacological profile of the thyroid hormone receptor antagonist NH3 in rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 322, Issue 1, 2007, Pages 385-390

  Grover, Gary J ^a   Dunn, Celeste ^a   Nguyen, Ngoc Ha ^c   Boulet, Jamie ^a   Dong, Gao ^a   Domogauer, Jason ^a   Barbounis, Peter ^a   Scanlan, Thomas S ^b  

^a Eurofins Medinet Inc   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HORMONE RECEPTOR BLOCKING AGENT; LIOTHYRONINE; THYROID HORMONE RECEPTOR ANTAGONIST NH3; THYROTROPIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CONTROLLED STUDY; DRUG MEGADOSE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; THYROTROPIN BLOOD LEVEL;

ANIMALS; BENZENE DERIVATIVES; CHOLESTEROL; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, THYROID HORMONE; THYROTROPIN; TRIIODOTHYRONINE;

EID: 34250763730     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.116152     Document Type: Article

References (29)

1. Arnold LA, Estebanex-Perpinas E, Togashi M, Jouravel N, Shelat A, McReynolds AC, Mar E, Nguyen P, Baxter JD, Fletterick RJ, et al. (2005) Discovery of small molecule inhibitors of the interaction of the thyroid hormone receptor with transcriptional coregulators. J Biol Chem 280:43048-43055.
2. 1 receptor protein. Endocrinology 134:1665-1670.
3. Carlsson B, Singh BN, Temciuc M, Nilsson S, Li YL, Mellin C, and Malm J (2002) Synthesis and preliminary characterization of a novel aniarrhythmic compound (KB-130015) with an improved toxicity profile compared with amiodarone. J Med Chem 45:623-630.
4. Chalmers DK, Munro SL, Iskander MN, and Craik DJ (1992) Models for the binding of amiodarone to the thyroid hormone receptor. J Comput Aided Mol Des 6:19-31.
5. Chiellini G, Apriletti JW, Yosihhara HA, Baxter JD, Ribeiro RCJ, and Scanlan TS (1998) A high-affinity subtype-selective agonist ligand for the thyroid hormone receptor. Chem Biol 5:299-306.
6. Dow RL, Schnelier SR, Paight ES, Hank RF, Chiang P, and Cornelius P (2003) Discovery of a novel series of 6-azauracil-based thyroid hormone receptor ligands. potent, TRβ subtype-selective thyromimetics. Bioorg Med Chem Lett 13:379-382.
7. Forini F, Nicolini G, Balzan S, Ratto GM, Murze B, Vanini V, and Iervasi G (2004) Amiodarone inhibits the 3,5,3′-triiodothyronine-dependent increase of sodium/ potassium adenosine triphosphatase activity and concentration in human atrial myocardial tissue. Thyroid 14:493-499.
8. Forrest D and Vennström B (2000) Functions of thyroid hormone receptors in mice. Thyroid 10:41-52.
9. Green S, Kumar V, Theulaz I, Wahli W, and Chanbon P (1988) The N-terminal DNA-binding "zinc" finger of the oestrogen and glucocorticoid receptors determines target gene specificity. EMBO J 7:3037-3044.
10. Grover GJ, Egan D, Sleph PG, Beehler BC, Chiellini G, Nguyen N-H, Baxter JD, and Scanlan S (2004) Effects of the thyroid hormone receptor agonist GC-1 on metabolic rate and cholesterol in rats and primates: selective actions relative to 3,5,3′-triiodo-I-thyronine. Endocrinology 145:1656-1661.
11. Grover G, Mellstrom K, Ye L, Malm J, Li YL, Bladh LG, Sleph PG, Smith MA, George R, Vennstrom B, et al. (2003) Selective thyroid hormone receptorβ activation: a strategy for reduction of weight, cholesterol, and lipoprotein. (a) with reduced cardiovascular liability. Proc Natl Acad Sci U S A 100:10067-10072.
12. Hangeland JJ, Doweyko AM, Dejneka T, Friends TJ, Devasthale P, Mellstrom K, Sandberg J, Grynfarb M, Sack JS, Einspahr H, et al. (2004) Thyroid receptor ligands. Part 2: thyromimetics with improved selectivity for the thyroid hormone receptor beta. Bioorg Med Chem Lett 14:3549-3553.
13. Harvey CB and Williams GR (2002) Mechanism of thyroid hormone action. Thyroid 12:441-446.
14. Johansson C, Vennström B, and Thoren P (1998) Evidence that decreased heart rate in thyroid hormone receptor-α1-deficient mice is an intrinsic defect. Am J Physiol 275:R640-R646.
15. Lim W, Nguyen N-H, Yang HY, Scanlan TS, and Furlow JD (2002) A thyroid hormone antagonist that inhibits thyroid hormone action in vivo. J Biol Chem 277:35665-35670.
16. Malm J (2004a) Therapeutic thyroid hormone ligand patents 1999-2003. Expert Opin Ther Pat 14:1169-1183.
17. Malm J (2004b) Thyroid hormone ligands and metabolic diseases. Curr Pharm Des 10:3525-3532.
18. Moore JMR, Galicia SJ, McReynolds AC, Nguyen N-H, Scanlan TS, and Guy RK (2004) Quantitative proteomics of the thyroid hormone receptor-coregulator interactions. J Biol Chem 279:27584-27590.
19. Nguyen NH, Apriletti JW, Baxter JD, and Scanlan TS (2005) Hammett analysis of selective thyroid hormone receptor modulators reveals structural and electronic requirements for hormone antagonists. J Am Chem Soc 127:4599-4608.
20. Nguyen NH, Apriletti JW, Cunha Lima ST, Webb P, Baxter JD, and Scanlan TS (2002) Rational design and synthesis of a novel thyroid hormone antagonist that blocks coactivator recruitment. J Med Chem 45:3310-3320.
21. Nguyen NH, Apriletti JW, Cunha ST, Webb P, Baxter JD, and Scanlan TS (2002) Rational design and synthesis of a novel thyroid hormone antagonist that blocks coactivator recruitment. J Med Chem 45:3310-3320.
22. Renaud JP, Rochel N, Ruff M, Vivat V, Chambon P, Gronemeyer H, and Moras D (1995) Crystal structure of the RAR-gamma ligand-binding domain bound to all-trans retinoic acid. Nature 378:681-689.
23. Ribeiro MO, Apriletti JW, Wagner RL, West BL, Feng W, Huber R, Kushner P, Nilsson S, Scanlan TS, Fletterick RJ, et al. (1998) Mechanisms of thyroid hormone action: insights from X-ray crystallographic and functional studies. Rec Prog Horm Res 53:351-394.
24. Scanlan TS, Yoshihara HAI, Nguyen NH, and Chiellini G (2001) Selective thyromimetics: tissue-selective thyroid hormone analogs. Curr Opin Drug Discov Dev 4:614-622.
25. Trost S, Swanson E, Gloss B, Wang-Iverson DB, Zhang H, Volodarsky T, Grover GJ, Baxter JD, Chiellini G, Scanlan TS, et al. (2000) The thyroid hormone receptor-beta-selective agonist GC-1 differentially affects plasma lipids and cardiac activity. Endocrinology 141:3057-3064.
26. Van Beeren GC, Jong WM, Kaptein E, Visser TJ, Bakker O, and Wiersinga WM (2003) Dronerarone acts as a selective inhibitor of 3,5,3′- triiodothyronine binding to thyroid hormone receptor-α1: in vitro and in vivo evidence. Endocrinology 144:552-558.
27. Yen PM (2001) Physiological and molecular basis of thyroid hormone action. Physiol Rev 81:1097-1142.
28. Webb P (2004) Selective activators of thyroid hormone receptors. Expert Opin Investig Drugs 13:489-500.
29. Wikström L, Johansson C, Salto C, Barlow C, Campos, Barros A, Baas F, Forrest D, Thoren P, and Vennstrom B (1998) Abnormal heart rate and body temperature in mice lacking thyroid hormone receptor alpha-1. EMBO J 17:455-461.